Haichuang Pharmaceutical announced that the Phase IIa clinical trial data of HP515 tablets, a Class 1 innovative drug designed to treat metabolism-related steatohepatitis independently developed by the company, has been officially accepted by the American Liver Disease Research Association as a poster summarizing the latest breakthroughs at the 2026 conference. The final analysis showed that the average liver fat content in the 12th week of each dose group decreased by more than 50% compared to the baseline, and 3.5% in the placebo group.

Zhitongcaijing · 1d ago
Haichuang Pharmaceutical announced that the Phase IIa clinical trial data of HP515 tablets, a Class 1 innovative drug designed to treat metabolism-related steatohepatitis independently developed by the company, has been officially accepted by the American Liver Disease Research Association as a poster summarizing the latest breakthroughs at the 2026 conference. The final analysis showed that the average liver fat content in the 12th week of each dose group decreased by more than 50% compared to the baseline, and 3.5% in the placebo group.